Page last updated: 2024-08-26

sr141716 and Metabolic Syndrome

sr141716 has been researched along with Metabolic Syndrome in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	58 (89.23)	29.6817
2010's	6 (9.23)	24.3611
2020's	1 (1.54)	2.80

Authors

Authors	Studies
Bukachi, FO; Makamu, BL; Mwangi, PW	1
Baulmann, J; Grzesiak, A; Kappert, K; Kaschina, E; Kemnitz, UR; Kintscher, U; Lauer, D; Paulis, L; Slavic, S; Sommerfeld, M; Thöne-Reineke, C; Trappiel, M; Unger, T	1
Chatterjee, T; Ince, H; Nienaber, ChA; Rehders, TC; Ritz, A	1
Debaty, I; Halimi, S; Muller, M; Villaret, L	1
Atkinson, RD; DeLeve, LD; Kanel, GC; McCuskey, RS; Wang, X	1
Basile, I; Gary-Bobo, M; Maynadier, M	1
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U	1
Kew, ST; Loh, KY	1
Diane, A; Kelly, SE; Mangat, R; Novak, S; Proctor, SD; Russell, JC; Vine, DF; Wang, Y	1
Brown, MW; Deanfield, JE; Després, JP; Job, B; Kastelein, JJ; Nissen, SE; O'Leary, DH; Reuwer, AQ; Visseren, FL; Zabbatino, SM; Zhou, R	1
Abu-Lebdeh, H; Jensen, M; Klein, S; Mundi, M; Smith, SR; Toledo, FG; Triay, J	1
Ditrói, K; Kleiner, D	1
Bergholm, R; Hakkarainen, A; Kotronen, A; Lundbom, J; Lundbom, N; Rissanen, A; Santos, A; Sevastianova, K; Tiikkainen, M; Urjansson, M; Yki-Järvinen, H	1
Einecke, D	1
Aumiller, J	1
Kvasnicka, T	1
Cox, SL	1
Ducobu, J	1
Després, JP; Golay, A; Sjöström, L	1
Golay, A; Makoundou, V	1
Cannon, CP	1
Vinik, AI	1
Nesto, RW	1
Blackburn, GL; Waltman, BA	1
Aronne, LJ; Devin, J; Heshmati, HM; Pi-Sunyer, FX; Rosenstock, J	1
Tonstad, S	1
Cannon, CP; Gelfand, EV	2
Esposito, K; Giugliano, D	1
Davis, SN	1
Thompson, CA	1
Behn, A; Ur, E	1
Després, JP; Golay, A; Hanotin, C; Pi-Sunyer, X; Scheen, AJ; Van Gaal, LG	1
Halford, JC; Harrold, JA; Kirkham, TC; Tucci, SA	1
Ahmed, MH	2
Wierzbicki, AS	1
Connell, JM; Ritchie, SA	1
Fujioka, K	1
Kyrou, I; Tsigos, C; Valsamakis, G	1
Stiefelhagen, P	1
Cervino, C; Pagotto, U; Pasquali, R	1
Hollander, P	1
Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP	1
Griffing, GT	1
Broncel, M; Koziróg, M	1
Scheen, AJ; Van Gaal, LF	1
Arnone, M; Bensaid, M; Chabbert, M; Croci, T; Cruccioli, N; Elachouri, G; Gallas, JF; Gary-Bobo, M; Herbert, JM; Janiak, P; Lacheretz, F; Le Fur, G; Maffrand, JP; Marini, P; Oury-Donat, F; Pfersdorff, C; Ravinet-Trillou, C; Roque, C; Scatton, B; Soubrié, P	1
Bloch, MJ; Bronander, KA	1
Wirth, A	1
Després, JP	1
Watson, KE	1
Van Gaal, L	1
Cannon, CP; Dibble, CT; Gelfand, EV	1
Al-Zaman, Y; Aylwin, S	1
Davis, SN; Perkins, JM	1
Bhatt, DL; Cannon, CP; Deanfield, JE; Després, JP; Gaudin, C; Hu, B; Job, B; Kapadia, S; Kastelein, JJ; Lincoff, AM; Nicholls, SJ; Nissen, SE; Rodés-Cabau, J; Ruzyllo, W; Steinhubl, SR; Tuzcu, EM; Wolski, K; Yasin, M	1
Nallamothu, BK; Rumsfeld, JS	1
Hanotin, C; Rissanen, AM; Rössner, S; Scheen, AJ; Van Gaal, LF; Ziegler, O	1
Scheen, AJ	1
Di Marzo, V; Szallasi, A	1
Bauersachs, J; Ertl, G; Fiedler, S; Neumüller, J; Pfrang, J; Schäfer, A	1

Reviews

34 review(s) available for sr141716 and Metabolic Syndrome

Article	Year
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. La Revue de medecine interne, 2008, Volume: 29, Issue:11 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones	2008
Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant. Drug discovery today, 2009, Volume: 14, Issue:3-4 Topics: Adiponectin; Adipose Tissue; Animals; Anti-Obesity Agents; Body Fat Distribution; Clinical Trials as Topic; Drug Delivery Systems; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant	2009
Endocannabinoid system and cardio-metabolic risk. The Medical journal of Malaysia, 2008, Volume: 63, Issue:4 Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2008
[The potential use of cannabidiol in the therapy of metabolic syndrome]. Orvosi hetilap, 2012, Apr-01, Volume: 153, Issue:13 Topics: Adipocytes; Appetite Depressants; Atherosclerosis; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Progression; Humans; Hyperphagia; Ischemia; Metabolic Syndrome; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant	2012
[Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. Casopis lekaru ceskych, 2005, Volume: 144, Issue:2 Topics: Arachidonic Acids; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Smoking; Smoking Cessation; Weight Loss	2005
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:8 Topics: Animals; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking Cessation	2005
[New obesity and metabolic syndrome treatment: rimonabant]. Revue medicale suisse, 2006, Jan-04, Volume: 2, Issue:47 Topics: Eating; Humans; Insulin Resistance; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant	2006
The endocannabinoid system: a new approach to control cardiovascular disease. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Appetite Regulation; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; History, 20th Century; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2005
The metabolic basis of atherogenic dyslipidemia. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones	2005
Managing cardiovascular risk inpatients with metabolic syndrome. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Cardiovascular Diseases; Exercise; Feeding Behavior; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors	2005
Pharmacotherapy to reduce visceral fat. Clinical cornerstone, 2005, Volume: 7, Issue:2-3 Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdominal Fat; Lactones; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant	2005
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain	2006
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:3 Topics: Animals; Disease Management; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking; Smoking Cessation	2006
Contemporary strategies for managing cardiometabolic risk factors. Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:1 Suppl Topics: Abdomen; Adipose Tissue; Bariatric Surgery; C-Reactive Protein; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Diet, Reducing; Exercise; Humans; Life Style; Metabolic Syndrome; Piperidines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Rimonabant; Risk Factors; United States	2006
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. Journal of the American College of Cardiology, 2006, May-16, Volume: 47, Issue:10 Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation	2006
The obesity epidemic and its cardiovascular consequences. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio	2006
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]. Revue medicale suisse, 2006, Aug-23, Volume: 2, Issue:76 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Humans; Metabolic Syndrome; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2006
Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Current medicinal chemistry, 2006, Volume: 13, Issue:22 Topics: Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Smoking Cessation; Substance-Related Disorders	2006
Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy? Expert opinion on emerging drugs, 2006, Volume: 11, Issue:4 Topics: Disease Outbreaks; Glomerulonephritis; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; United Kingdom	2006
Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International journal of clinical practice, 2006, Volume: 60, Issue:12 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Factors; Smoking Cessation	2006
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2007, Volume: 17, Issue:4 Topics: Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tumor Necrosis Factor-alpha	2007
Metabolic syndrome treatment strategies. Pharmacotherapy, 2006, Volume: 26, Issue:12 Pt 2 Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Weight Loss	2006
The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Annals of the New York Academy of Sciences, 2006, Volume: 1083 Topics: Cannabinoid Receptor Modulators; Central Nervous System Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction	2006
Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. Mini reviews in medicinal chemistry, 2007, Volume: 7, Issue:1 Topics: Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant	2007
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. Journal of clinical pharmacology, 2007, Volume: 47, Issue:5 Topics: Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2007
[Rimonabant--a panacea for patients with metabolic syndrome?]. Polskie Archiwum Medycyny Wewnetrznej, 2006, Volume: 116, Issue:2 Topics: Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome	2006
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Vascular health and risk management, 2007, Volume: 3, Issue:2 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome	2007
Cardiovascular disease under the influence of excess visceral fat. Critical pathways in cardiology, 2007, Volume: 6, Issue:2 Topics: Adiponectin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Prospective Studies; Pyrazoles; Rimonabant; Risk Factors	2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss	2007
Reducing cardiometabolic risk through selective antagonism of CB1 receptors. Clinical cornerstone, 2007, Volume: 8 Suppl 6 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Assessment; Risk Factors	2007
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide	2008
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Current diabetes reports, 2008, Volume: 8, Issue:1 Topics: Cannabinoid Receptor Modulators; Clinical Trials as Topic; Endocannabinoids; Energy Metabolism; Feeding Behavior; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant	2008
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. Journal of neuroendocrinology, 2008, Volume: 20 Suppl 1 Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2008

Trials

10 trial(s) available for sr141716 and Metabolic Syndrome

Article	Year
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart (British Cardiac Society), 2011, Volume: 97, Issue:14 Topics: Anti-Obesity Agents; Canada; Carotid Arteries; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Obesity, Abdominal; Piperidines; Placebo Effect; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; United States; Waist Circumference; Weight Loss	2011
Does rimonabant independently affect free fatty acid and glucose metabolism? The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:3 Topics: Adult; Aged; Behavior Therapy; Body Composition; Cannabinoid Receptor Antagonists; Diet, Reducing; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Humans; Insulin; Intra-Abdominal Fat; Life Style; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2012
CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. International journal of obesity (2005), 2013, Volume: 37, Issue:5 Topics: Adult; Aged; Cannabinoid Receptor Antagonists; Double-Blind Method; Fatty Liver; Female; Finland; Humans; Liver; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Treatment Outcome; Weight Loss	2013
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine, 2005, Nov-17, Volume: 353, Issue:20 Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Triglycerides; Weight Loss	2005
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, Feb-15, Volume: 295, Issue:7 Topics: Adult; Aged; Anti-Obesity Agents; Blood Pressure; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss	2006
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. The American journal of medicine, 2007, Volume: 120, Issue:2 Suppl 1 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome	2007
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Current atherosclerosis reports, 2007, Volume: 9, Issue:5 Topics: Behavior; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2007
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA, 2008, Apr-02, Volume: 299, Issue:13 Topics: Aged; Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Diet, Reducing; Disease Progression; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Ultrasonography, Interventional	2008
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European heart journal, 2008, Volume: 29, Issue:14 Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Triglycerides; Weight Loss	2008

Other Studies

22 other study(ies) available for sr141716 and Metabolic Syndrome

Article	Year
Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design. The Pan African medical journal, 2023, Volume: 45 Topics: Adult; Animals; Anti-HIV Agents; Cannabinoids; Glucose Intolerance; HIV Infections; Humans; Lopinavir; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Rimonabant; Ritonavir; Zidovudine	2023
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of molecular medicine (Berlin, Germany), 2013, Volume: 91, Issue:7 Topics: Animals; Cannabinoid Receptor Antagonists; Cardiotonic Agents; Cells, Cultured; Collagen; Fibroblasts; Heart; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metabolic Syndrome; Myocardial Infarction; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Transforming Growth Factor beta1	2013
[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system]. Praxis, 2008, May-28, Volume: 97, Issue:11 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant	2008
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. The American journal of pathology, 2008, Volume: 173, Issue:4 Topics: Actins; Animals; Apolipoprotein A-I; Body Weight; Cells, Cultured; Diet; Disease Models, Animal; Fatty Liver; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Organ Size; Piperidines; Pyrazoles; Rimonabant	2008
The endocannabinoid system as a target for obesity treatment. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk	2008
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 299, Issue:2 Topics: Animals; Biomarkers; Blood Vessels; Body Weight; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Inflammation; Insulin Resistance; Intestinal Mucosa; Kidney Diseases; Kidney Glomerulus; Lipid Metabolism; Male; Metabolic Syndrome; Myocardial Ischemia; Piperidines; Prediabetic State; Pyrazoles; Rats; Rats, Mutant Strains; Renal Circulation; Rimonabant; Sclerosis; Thrombosis	2010
[A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Cannabinoid Receptor Antagonists; Coronary Artery Disease; Dose-Response Relationship, Drug; Humans; Lipids; Metabolic Syndrome; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Smoking Cessation; United States; Weight Loss	2004
[Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?]. MMW Fortschritte der Medizin, 2004, Nov-04, Volume: 146, Issue:45 Topics: Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss	2004
[In diabetes cannabinoid antagonist kills two birds with one stone]. MMW Fortschritte der Medizin, 2005, Sep-01, Volume: 147, Issue:35-36 Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Controlled Clinical Trials as Topic; Diabetes Mellitus; Glycated Hemoglobin; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2005
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. Revue medicale de Bruxelles, 2005, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Piperidines; Pyrazoles; Rimonabant	2005
Optimal treatments for the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones	2006
Treatments for metabolic syndrome may expand. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, May-15, Volume: 63, Issue:10 Topics: Anti-Obesity Agents; Dietary Supplements; Humans; Insulin Resistance; Magnesium; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; Risk Factors	2006
[Rimonabant actions on cardiometabolic risk factors]. Medizinische Monatsschrift fur Pharmazeuten, 2007, Volume: 30, Issue:1 Topics: Cardiovascular Diseases; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2007
Cardiometabolic risk modification: current trends and emerging therapies. JAAPA : official journal of the American Academy of Physician Assistants, 2006, Volume: Suppl Cardiometabolic Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain	2006
Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome. MedGenMed : Medscape general medicine, 2006, Oct-09, Volume: 8, Issue:4 Topics: Brain; Cannabinoid Receptor Modulators; Cannabis; Endocannabinoids; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant	2006
Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention. Saudi medical journal, 2007, Volume: 28, Issue:5 Topics: Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus; Humans; Metabolic Syndrome; Middle East; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Saudi Arabia	2007
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (Baltimore, Md.), 2007, Volume: 46, Issue:1 Topics: Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Inflammation; Liver; Male; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA; Tumor Necrosis Factor-alpha	2007
[A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)]. MMW Fortschritte der Medizin, 2006, Nov-16, Volume: 148, Issue:46 Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Drug Approval; Germany; Humans; Insurance, Pharmaceutical Services; Life Style; Metabolic Syndrome; National Health Programs; Obesity; Piperidines; Pyrazoles; Quality of Life; Rimonabant	2006
[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval]. MMW Fortschritte der Medizin, 2007, Jun-28, Volume: 149, Issue:27-28 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoids; Central Nervous System; Central Nervous System Diseases; Drug Approval; Germany; Humans; Mental Disorders; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss	2007
The hope and fear of rimonabant. JAMA, 2008, Apr-02, Volume: 299, Issue:13 Topics: Atherosclerosis; Humans; Metabolic Syndrome; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk	2008
Rimonabant in rats with a metabolic syndrome: good news after the depression. British journal of pharmacology, 2008, Volume: 154, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant	2008
The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. British journal of pharmacology, 2008, Volume: 154, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Chemokine CCL2; Chemokine CCL5; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glucose Intolerance; Inflammation Mediators; Leukocyte Count; Leukocytes; Lipids; Male; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Weight Gain	2008